Physician perceptions to use of trastuzumab in HER2+breast cancer in India

被引：0
|
作者：
Ramanjinappa, N. [1 ]
Agarwal, J. [1 ]
Upveja, K. H. [1 ]
机构：
[1] Viatris, Dept Med Affairs, Bengaluru, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页码：S1437 / S1437
页数：1
相关论文
共 50 条
  • [31] Subcutaneous trastuzumab for the treatment of HER2+breast cancer in Canada: A cost-minimization study
    Coombes, Megan
    Yin, Lori
    Liu, Ingrid
    Shek, Norman
    Rusu, Flavia
    Mukherjee, Som
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [32] Generation, characterization, and maintenance of trastuzumab-resistant HER2+breast cancer cell lines
    Zazo, Sandra
    Gonzalez-Alonso, Paula
    Martin-Aparicio, Ester
    Chamizo, Cristina
    Cristobal, Ion
    Arpi, Oriol
    Rovira, Ana
    Albanell, Joan
    Eroles, Pilar
    Lluch, Ana
    Madoz-Gurpide, Juan
    Rojo, Federico
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (11): : 2661 - +
  • [33] Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+Breast Cancer
    Munoz, Caroline
    Tai, Xiaochen
    Arias, Jessica
    Eisen, Andrea
    Chaudhry, Munaza
    Gavura, Scott
    Chan, Kelvin K. W.
    [J]. CURRENT ONCOLOGY, 2024, 31 (03) : 1633 - 1644
  • [34] Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+Breast Cancer
    Franco-Mateos, Emma
    Souza-Egipsy, Virginia
    Garcia-Estevez, Laura
    Perez-Garcia, Jose
    Gion, Maria
    Garrigos, Laia
    Cortez, Patricia
    Saavedra, Cristina
    Gomez, Patricia
    Ortiz, Carolina
    Cruz, Victor L.
    Ramos, Javier
    Cortes, Javier
    Vega, Juan F.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [35] Genomic alterations associated with HER2+breast cancer risk and clinical outcome in response to trastuzumab
    Singla, Heena
    Kaur, Raman Preet
    Shafi, Gowhar
    Vashistha, Rajesh
    Banipal, Raja Paramjeet Singh
    Kumar, Vinod
    Munshi, Anjana
    [J]. MOLECULAR BIOLOGY REPORTS, 2019, 46 (01) : 823 - 831
  • [36] Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+breast cancer.
    McLaughlin, Shannon
    Nakajima, Erika
    Isakoff, Steven J.
    Shin, Jennifer
    Moy, Beverly
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] AXL is a potential druggable target in trastuzumab resistance in HER2+breast cancer patients.
    Adam-Artigues, Anna
    Cervera, Raimundo
    Javier Arenas, Enrique
    Braso-Maristany, Fara
    Martinez-Sabadell, Alex
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Simon, Soraya
    Poveda, Jesus
    Burgues, Octavio
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Eroles, Pilar
    Prat, Aleix
    Arribas, Joaquin
    Miguel Cejalvo, Juan
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [38] Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+breast cancer
    Gropper, A.
    Burstein, H. J.
    Harris, L.
    Anderson, K. S.
    Gold, J. M.
    Younger, W. J.
    Bunnell, C. A.
    Najita, J. S.
    Winer, E. P.
    Mayer, E. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Antitumor properties of bromelain loaded trastuzumab conjugated niosomes in HER2+breast cancer cells
    Tut, Ezgi
    Guldu, Ozge Kozgus
    Medine, Emin Ilker
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 101
  • [40] Effect of Trastuzumab and Lonidamine-Loaded Lipid Nanoparticles (LNP) on HER2+Breast Cancer
    Zurnaci, Fatma Ozlem
    Kurtulus, Sukran Ozdatli
    Turk, Ceyda Tuba Sengel
    Hascicek, Canan
    Guzel, Mustafa
    [J]. CHEMISTRYSELECT, 2024, 9 (22):
12345